A new study from Ohio State University and University of Toronto researchers concludes that the detrimental effect of Sarbanes-Oxley on U.S. stock markets is "overblown," according to BloggingStocks writer Tom Taulli. In fact, the research revealed that foreign companies listing in the U.S. still draw a premium from their investors -- presumably in exchange for meeting the strict listing requirements. There is no evidence, the authors say, that Sarbox has harmed the U.S. exchanges.
Research notwithstanding, Taulli advises, don't expect private equity firms to ease up on knocking Sarbox. After all, studies like this one don't get much ink.